US00847G8042 - Common Stock
AGENUS INC
NASDAQ:AGEN (12/6/2024, 8:00:00 PM)
After market: 3.6 +0.02 (+0.56%)3.58
+0.44 (+14.01%)
Agenus Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Lexington, Massachusetts and currently employs 389 full-time employees. The company went IPO on 2000-02-04. Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. The company is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
AGENUS INC
3 Forbes Rd
Lexington MASSACHUSETTS 02421
P: 17816744400
CEO: Garo H. Armen
Employees: 389
Website: https://agenusbio.com/
AGEN earnings call for the period ending September 30, 2024.
Here you can normally see the latest stock twits on AGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: